Treatment of recurrent myelodysplastic syndrome (MDS) after hematopoietic cell transplantation (HCT) remains challenging. We present a 4-year-old girl experiencing early MDS relapse post-HCT treated with a multimodal strategy encompassing a second HCT and innovative targeted therapies. We underscore the potential of a comprehensive treatment approach in managing recurrent pediatric MDS.
Competing Interests: Franziska Wachter, Yana Pikman, Jacob Bledsoe, Malika Kapadia, Susanne Baumeister, Jared Rowe, Akiko Shimamura, Jennifer Whangbo, Leslie Lehmann, John Horan declare no relevant conflict of interest. Andrew E. Place has received research funding from AbbVie, Inc. Susan Prockop receives support for the conduct of clinical trials through Boston Children's Hospital from AlloVir, Atara, and Jasper, Susan Prockop provides consulting (CellEvolve, Pierre Fabre) and receives honoraria from Regeneron, Susan Prockop is an Inventor related to development of third party viral specific T cells program with all rights assigned to Memorial Sloan Kettering Cancer Center. JAP receives support for the conduct of clinical trials through Boston Children's Hospital / Dana‐Farber Cancer Institute from AbbVie, Ymab Therapeutics and Servier and is on the advisory board for foresee pharmaceuticals.
(© 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)